Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

All included stronger effects in women compared to men, e.g., gout for hospitalised COVID-19 (women: HR: 2.56, 95%-CI 2.21 to 2.96, p-value: 1.3x10−36; men: HR: 1.46, 95%-CI: 1.34 to 1.58, p-value: 2.1 x 10−19), among Europeans reporting vitamin D deficiencies (Europeans: HR: 2.31, 95%-CI: 2.13 to 2.51, p-value: 2.1 x 10−87; non-Europeans: HR: 1.31, 95%-CI: 1.08 to 1.60, p-value = 5.5 x 10−3), or among younger participants, e.g., disorders of magnesium metabolism and death with COVID-19 as a likely result of renal failure (age ≤ 65 years: HR: 42.98, 95%-CI: 20.10 to 91.90, p-value: 3.0 x 10−22; age > 65 years: HR: 5.35, 95%-CI: 3.51 to 8.16, p-value: 5.9 x 10−15).

Source: Disease risk profiles for COVID-19 and Long COVID. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Review / evidence synthesis.

Review / evidence synthesis

Reviews existing research; the exact review methods need further assessment.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

To establish endpoint-specific associations, we performed meta-analysis across disease associations for all three COVID-19 endpoints derived using the R package metafor (v.3.8.1).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Complex patterns of multimorbidity associated with severe COVID-19 and long COVID

Review / evidence synthesis · Communications Medicine · 2024

Original publication title

Complex patterns of multimorbidity associated with severe COVID-19 and long COVID

Maik Pietzner; Spiros Denaxas; Summaira Yasmeen; Maria A. Ulmer; Tomoko Nakanishi; Matthias Arnold; Gabi Kastenmüller; Harry Hemingway; Claudia Langenberg

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Our results provide a unique reference that demonstrates how 1) complex co-occurrence of multiple: including non-fatal: conditions predispose to increased COVID-19 severity and 2) how incorporating the whole breadth of medical diagnosis can guide the interpretation of genetic risk loci.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Early evidence that patients with (multiple) pre-existing diseases are at highest risk for severe COVID-19 has been instrumental in the pandemic to allocate critical care resources and later vaccination schemes. However, systematic studies exploring the breadth of medical diagnoses are scarce but may help to understand severe COVID-19 among patients at supposedly low risk.

Source: Background

Abstract: What methods does the paper describe?

We systematically harmonized >12 million primary care and hospitalisation health records from ~500,000 UK Biobank participants into 1448 collated disease terms to systematically identify diseases predisposing to severe COVID-19 (requiring hospitalisation or death) and its post-acute sequalae, Long COVID.

Source: Methods

Abstract: Results

Here we identify 679 diseases associated with an increased risk for severe COVID-19 (n = 672) and/or Long COVID (n = 72) that span almost all clinical specialties and are strongly enriched in clusters of cardio-respiratory and endocrine-renal diseases. For 57 diseases, we establish consistent evidence to predispose to severe COVID-19 based on survival and genetic susceptibility analyses. This includes a possible role of symptoms of malaise and fatigue as a so far largely overlooked risk factor for severe COVID-19.

We finally observe partially opposing risk estimates at known risk loci for severe COVID-19 for etiologically related diseases, such as post-inflammatory pulmonary fibrosis or rheumatoid arthritis, possibly indicating a segregation of disease mechanisms.

Source: Results

Abstract: Conclusions

Our results provide a unique reference that demonstrates how 1) complex co-occurrence of multiple: including non-fatal: conditions predispose to increased COVID-19 severity and 2) how incorporating the whole breadth of medical diagnosis can guide the interpretation of genetic risk loci.

Source: Conclusions
Authors’ abstract

Background

Early evidence that patients with (multiple) pre-existing diseases are at highest risk for severe COVID-19 has been instrumental in the pandemic to allocate critical care resources and later vaccination schemes. However, systematic studies exploring the breadth of medical diagnoses are scarce but may help to understand severe COVID-19 among patients at supposedly low risk.

Methods

We systematically harmonized >12 million primary care and hospitalisation health records from ~500,000 UK Biobank participants into 1448 collated disease terms to systematically identify diseases predisposing to severe COVID-19 (requiring hospitalisation or death) and its post-acute sequalae, Long COVID.

Results

Here we identify 679 diseases associated with an increased risk for severe COVID-19 (n = 672) and/or Long COVID (n = 72) that span almost all clinical specialties and are strongly enriched in clusters of cardio-respiratory and endocrine-renal diseases. For 57 diseases, we establish consistent evidence to predispose to severe COVID-19 based on survival and genetic susceptibility analyses. This includes a possible role of symptoms of malaise and fatigue as a so far largely overlooked risk factor for severe COVID-19.

We finally observe partially opposing risk estimates at known risk loci for severe COVID-19 for etiologically related diseases, such as post-inflammatory pulmonary fibrosis or rheumatoid arthritis, possibly indicating a segregation of disease mechanisms.

Conclusions

Our results provide a unique reference that demonstrates how 1) complex co-occurrence of multiple: including non-fatal: conditions predispose to increased COVID-19 severity and 2) how incorporating the whole breadth of medical diagnosis can guide the interpretation of genetic risk loci.

Plain Language Summary

Early in the COVID-19 pandemic it was clear that people with multiple chronic diseases were vulnerable and needed special protection, such as shielding. However, many people without such diseases required hospital care or died from COVID-19. Here, we investigated the importance of underlying diseases, including mild diseases not requiring hospitalization, for COVID-19 outcomes. Using information from electronic health records we find that many severe, but also less severe diseases increase the risk for severe COVID-19 and its impact on health even months after acute infection (Long COVID).

This included an almost two-fold higher risk among people that reported poor well-being and fatigue. Our findings show the value of using primary care health records and the need to consider all the medical history of patients to identify those in need of special protection.

Pietzner et al. demonstrate the need for a holistic approach to identify people at highest risk for severe COVID-19 based on integrating health records across primary and secondary care. Integrating human genetic evidence, they find that the symptoms of malaise and fatigue are a largely unrecognized risk factor for severe COVID-19.

Publication and source details

Original title: Complex patterns of multimorbidity associated with severe COVID-19 and long COVID

Maik Pietzner; Spiros Denaxas; Summaira Yasmeen; Maria A. Ulmer; Tomoko Nakanishi; Matthias Arnold; Gabi Kastenmüller; Harry Hemingway; Claudia Langenberg

Communications Medicine · 2024

© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T10:35:20.498796+00:00

DOI: 10.1038/s43856-024-00506-x · PMC11231221